Liver metastases and its prognostic significance in men with metastatic prostate cancer

Liver metastases predicts shorter overall survival in men with metastatic castration-refractory prostate cancer (mCRPC), according to data being presented at the 2012 American Society of Clinical Oncology Annual Meeting in Chicago.

In a phase III trial, lead study author William Kevin Kelly, DO, Thomas Jefferson University Hospital and the Kimmel Cancer Center at Jefferson, and colleagues from the Alliance for Clinical Trials in Oncology, found that men without lived 8.2 months longer compared to men whose cancer did metastasize, despite both groups having similar progression free survival and response to based chemotherapy.

The multi-institutional study included 1,050 patients from the CALGB 90401 trial, a randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with mCRPC.

For the investigation, researchers assessed the prognostic significance of liver metastases in predicting overall survival and progression free survival, adjusting for stratification factors.

Fifty-nine (5.6%) of those patients had documented liver metastases. Patients with liver metastases had higher baseline alkaline phosphatase (ALK) and lactate dehydrogenase (ADH) levels compared to patients without liver metastases. The median overall survival time in patients with liver metastases was 14.4 compared to 22.6 months for patients without liver metastasis(hazard ratio (HR) 1.4) . The HR for treatment effect (docetaxel and prednisone with either bevacizumab or placebo) for liver was not statistically significant for either group.

More information: Abstract # 4655, Sunday, June 3, 8:00 AM - 12:00 PM CST, S Hall A2. abstract.asco.org/AbstView_114_96038.html

add to favorites email to friend print save as pdf

Related Stories

Docetaxel given after doxorubicin reduces recurrence

Jan 08, 2008

Adding the drug docetaxel to anthracycline-based chemotherapy slightly improved disease-free survival in breast cancer patients, according to a randomized clinical trial published online January 8 in the Journal of the Na ...

Recommended for you

Finding the way to lung tumours by 'GPS'

1 hour ago

The innumerable divisions of the bronchi often turn the hunt for tumours in the lungs into a game of chance. But soon, lung specialists will be able to navigate accurately inside the airways by "GPS".

Study suggests new approach to fight lung cancer

15 hours ago

Recent research has shown that cancer cells have a much different – and more complex – metabolism than normal cells. Now, scientists at The University of Texas at Dallas have found that exploiting these differences might ...

Study evaluates procedures for diagnosing sarcoidosis

16 hours ago

Among patients with suspected stage I/II pulmonary sarcoidosis who were undergoing confirmation of the condition via tissue sampling, the use of the procedure known as endosonographic nodal aspiration compared with bronchoscopic ...

User comments

More news stories

Laughing gas does not increase heart attacks

(Medical Xpress)—Nitrous oxide—best known as laughing gas—is one of the world's oldest and most widely used anesthetics. Despite its popularity, however, experts have questioned its impact on the risk ...

Model recreates wear and tear of osteoarthritis

(Medical Xpress)—There's a reason osteoarthritis is often called wear-and-tear arthritis: Repeated stress on joints over time results in degeneration of the soft cartilage that normally distributes loads ...